Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Conditions
Brief summary
This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies have shown that patients with prostate cancer, who have been treated with standard medical therapy that lowers testosterone levels, have an increased risk of these changes. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells instead of lowering testosterone levels. It is not yet known whether prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who receive standard androgen deprivation therapy.
Detailed description
PRIMARY OBJECTIVES: I. To determine the incidence of metabolic syndrome within 12 months, as defined by the Adult Treatment Panel III, in patients treated with enzalutamide compared to standard androgen deprivation therapy. SECONDARY OBJECTIVES: I. To determine the incidence of metabolic syndrome within 6 months, as defined by the Adult Treatment Panel III, in patients treated with enzalutamide compared to standard androgen deprivation therapy. II. To assess bone health, as measured by a dual-energy x-ray absorptiometry (DXA) scanner. III. To assess body composition (sarcopenic obesity), as measured by a DXA scanner. IV. To assess quality of life (QOL), as measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Sexual Health Inventory in Men (SHIM). V. To assess time to prostate-specific antigen (PSA) progression and time to radiographic progression. VI. To assess the incidence of developing individual risk factors, or components, which comprise metabolic syndrome. VII. To assess the change in high-sensitivity C-reactive protein (hs-CRP) as a marker of inflammation. VIII. To assess the safety and tolerance of enzalutamide or androgen deprivation therapy (ADT). IX. To assess the change in physical function as measured by the Short Physical Performance Battery (SPPB). OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive enzalutamide orally (PO) once daily (QD) for 12 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix subcutaneously (SC) or intramuscularly (IM) for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT. After completion of study treatment, patients are followed up at 30 days.
Interventions
DRUGEnzalutamide
Given PO
DRUGleuprolide acetate
Given SC or IM
DRUGgoserelin acetate
Given SC or IM
Given SC or IM
DRUGtriptorelin
Given SC or IM
DRUGdegarelix
Given SC or IM
Sponsors
University of Colorado, Denver
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically proven adenocarcinoma of the prostate; if pathology is unavailable, the principal investigator (PI) may also make a determination of prostate cancer based on unequivocal clinic data * Patients with advanced prostate cancer suitable for systemic treatment defined as: having metastatic disease, a biochemical relapse after primary therapy, or patients in whom primary therapy is not appropriate or feasible; patients without metastatic disease will need evaluation for local therapy and deemed inappropriate or have refused this treatment option * Eastern Cooperative Oncology Group (ECOG) 0-2 * Age \> 18 years * Must use a condom if having sex with a pregnant woman * A male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration * Life expectancy estimated at \> 12 months * Ability to understand and willingness to provide written informed consent document
Exclusion criteria
* A history of androgen deprivation therapy; patients receiving hormonal therapy in the adjuvant and/or neoadjuvant setting must have discontinued therapy at least 6 months prior to day 1 of treatment AND have a serum testosterone level \>= 50 ng/dL AND cannot have received more than 18 months of previous ADT * A history of orchiectomy * Previous androgen blockade (e.g. antiandrogens) in the last 3 months * Patients already meeting the criteria for metabolic syndrome as defined by the Adult Treatment Panel III Criteria which requires 3/5 parameters encompassing glucose control, blood pressure, lipids and waist circumference; patients with 2 of the parameters at baseline will be allowed enrollment provided that one of those risk factors is hypertension (\>= 130/\>= 85 mm Hg) * Baseline hypogonadism as defined as a testosterone \< 50 ng/dL * PSA \< 0.5 ng/dL * Serum vitamin D 25, hydroxy (OH) \< 12 ng/mL * Active hepatitis C virus * Use of corticosteroids as defined by a daily dose of prednisone (or equivalent) of 5 mg or greater for more than 1 month continuously within 3 months of screening * Corrected calcium \> 10.6 mg/dL * Absolute neutrophil count \< 1500/uL * Platelet count \< 100,000/uL * Hemoglobin \< 9 g/dL * Total bilirubin \>= 1.5 x upper limit of normal (ULN) (unless documented Gilbert's) * Alanine aminotransferase or aspartate aminotransferase \>= 2.5 x ULN * Creatinine \> 2 mg/dL * Clinically significant cardiovascular disease as evidenced by: myocardial infarction within 6 months of screening; uncontrolled angina within 3 months of screening; New York Heart Association (NYHA) class 3 or 4 congestive heart failure; clinically significant ventricular arrhythmia; Mobitz II/2nd degree/or 3rd degree heart block without a pacemaker in place; uncontrolled hypertension (HTN) (systolic \> 180 mmHg or diastolic \> 105 mmHg at screening) * Previous exposure to enzalutamide * Use of an investigational therapeutic within 30 days * History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agent * Known or suspected brain metastasis or active leptomeningeal disease * History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past; also, history of loss of consciousness or transient ischemic attack within 12 months of day 1 visit * Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria | Within the first 12 months of therapy | Metabolic syndrome will be assessed at the beginning of each course and defined by the presence of 3 of the following five traits: abdominal obesity, defined as a waist circumference \> 102 cm (\> 40 in); serum triglycerides \>= 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides; serum high density lipoprotein (HDL) cholesterol \< 40 mg/dL (1 mmol/L) or drug treatment for low HDL; blood pressure \>= 130/\>= 85 mmHg or drug treatment for elevated blood pressure; and fasting plasma glucose (FPG) \>= 100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Bone Turnover Markers, as Measured by Bone-specific Alkaline Phosphatase | Baseline and month 12 | Will be assessed for each treatment group. Measurements will be taken at day 1 of each course. A paired t-test will test within an arm as to whether the change from baseline to 12 months is significantly different from zero. |
| Change in Bone Density | Baseline to 12 months | We will measure bone density via a DXA scanner, Left Femur and Right femur T scores will be added to a composite score. A paired t-test will test within an arm as to whether the change from baseline to twelve months is significantly different from zero. The T-score is the standard deviation of how much bone density differs from the bone mass of an average healthy 30 year old. A score of 0 indicates no deviation from average. The following ranges are used: * T-score of -1.0 or above = normal bone density * T-score between -1.0 and -2.5 = low bone density, or osteopenia * T-score of -2.5 or lower = osteoporosis |
| Change in Free Fat Mass, as Measured by a DXA Scanner | Baseline to up to 12 months | A paired t-test will test within an arm as to whether the change from baseline to each time point is significantly different from zero. These data are not able to be reported as the DXA did not measure free fat mass and thus we will be using cross sectional CT analysis. |
| Change in Fat Mass, as Measured by a DXA Scanner | Baseline to up to 12 months | A paired t-test will test within an arm as to whether the change from baseline to each time point is significantly different from zero. |
| Change in Quality of Life (QOL) Scores, as Measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Sexual Health in Men (SHIM) | Baseline to up to 7 months | The FACT-P is the Functional Assessment of Cancer Therapy - Prostate and measures physical/emotional quality of life in prostate cancer patients. NUMBER OF ITEMS:39 PATIENT POPULATION:Prostate cancer patients 18 years and older RECALL PERIOD:Past 7 days RESPONSE SCALE:5 point Likert-type scale SUBSCALE DOMAINS: Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), Prostate Cancer Subscale (PCS) SCORING: Scores range from 0-158. In general, the higher the score, the better the quality of life. Sexual Health in Men (SHIM). 5 item measure of erectile function. Total score is 1-25 with a higher score indicating better sexual health. Scores: no ED (SHIM total score, 22-25), mild (17-21), mild to moderate (12-16), moderate (8-11), and severe ED (1-7). |
| Metabolic Syndrome Incidence, Summarized by the Proportion of Patients With at Least 3 of the 5 Pre-specified Criteria | Within the first 6 months of therapy | Metabolic syndrome will be assessed at the beginning of each course and defined by the presence of 3 of the following five traits: abdominal obesity, defined as a waist circumference \> 102 cm (\> 40 in); serum triglycerides \>= 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides; serum HDL cholesterol \< 40 mg/dL (1 mmol/L) or drug treatment for low HDL; blood pressure \>= 130/\>= 85 mmHg or drug treatment for elevated blood pressure; and FPG \>= 100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose. |
| Time to Radiographic Progression | Time from randomization to the earliest objective evidence of radiographic progression as defined per protocol, assessed up to 30 days after the last dose of study drug | Log rank test will be used to compare the distributions of above variables between the group treated with enzalutamide to the group on standard ADT. |
| Change in Markers of Inflammation, as Measured by Circulating Hs-CRP | Difference between baseline and 12 months. | Mean change in available samples from baseline to 12 months, presented in mg/dL |
| Incidence of Adverse Events, Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.1 | Up to 30 days after the last dose of study drug | The incidence of adverse events has been reported in the adverse events log for clinicaltrials.gov |
| Change in Physical Function, as Measured by Short Physical Performance Battery (SPPB). | Difference between baseline and 12 months. | The Short SPPB incorporates 3 validated portions to assess a patient's balance and mobility. SPPB scores range from zero to 12 possible points. SPPB score of 3-9 points in persons with no mobility disability indicates frailty; SPPB score of 10 or greater for persons with no sarcopenia and no mobility disability indicates robustness. The higher the score, the better the physical function. Will be measured as a continuous outcome. |
| Change in Bone Turnover Markers as Measured by N-telopeptide | Baseline and 12 months | Will be assessed for each treatment group. Measurements will be taken at day 1 of each course. A paired t-test within an arm as to whether the change from baseline to 12 months is significantly different from zero. N-Telopeptide units - nM Bone Collagen Equivalent (BCE). |
| Number of Patients With PSA Progression | Time from randomization to the earliest objective evidence of PSA progression as defined per protocol, assessed up to 30 days after the last dose of study drug | PSA progression as defined by an increase in \>= 50% from nadir and an absolute increase of at least 2 ng/mL above the nadir, occurring at least 12 weeks after start of therapy that is confirmed by two consecutive increases taken at least 2 weeks apart. Log rank test will be used to compare the distributions of above variables between the group treated with enzalutamide to the group on standard ADT. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Enzalutamide) Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
Enzalutamide: Given PO | 10 |
| Arm II (ADT) Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
leuprolide acetate: Given SC or IM
goserelin acetate: Given SC or IM
histrelin acetate: Given SC or IM
triptorelin: Given SC or IM
degarelix: Given SC or IM | 9 |
| Total | 19 |
Baseline characteristics
| Characteristic | Arm II (ADT) | Total | Arm I (Enzalutamide) |
|---|---|---|---|
| Age, Continuous | 68 years | 66 years | 62 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 19 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Metastatic disease | 3 Participants | 7 Participants | 4 Participants |
| PSA value | 5.48 NG/ML | 7.55 NG/ML | 10.86 NG/ML |
| Region of Enrollment United States | 9 participants | 19 participants | 10 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 9 Participants | 19 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 1 / 9 |
| other Total, other adverse events | 10 / 10 | 9 / 9 |
| serious Total, serious adverse events | 1 / 10 | 3 / 9 |
Outcome results
Primary
Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria
Metabolic syndrome will be assessed at the beginning of each course and defined by the presence of 3 of the following five traits: abdominal obesity, defined as a waist circumference \> 102 cm (\> 40 in); serum triglycerides \>= 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides; serum high density lipoprotein (HDL) cholesterol \< 40 mg/dL (1 mmol/L) or drug treatment for low HDL; blood pressure \>= 130/\>= 85 mmHg or drug treatment for elevated blood pressure; and fasting plasma glucose (FPG) \>= 100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose.
Time frame: Within the first 12 months of therapy
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I (Enzalutamide) | Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria | 5 Participants |
| Arm II (ADT) | Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria | 3 Participants |
Comparison: The difference between metabolic syndrome and treatment were evaluated with the Chi-square testp-value: 0.46Chi-squared
Comparison: Cohort characteristics for Metabolic Syndrome were summarized by event and arm using counts and percentages for categorical variables and the mean, standard deviation, median, and quartiles for continuous variables. The difference between metabolic syndrome and treatment were evaluated with the Chi-square test. P-values are reported based on a null hypothesis of no difference against a two-sided alternative. Analyses were performed using SAS 9.4 (SAS Instp-value: 0.46Chi-squared
Secondary
Change in Bone Density
We will measure bone density via a DXA scanner, Left Femur and Right femur T scores will be added to a composite score. A paired t-test will test within an arm as to whether the change from baseline to twelve months is significantly different from zero. The T-score is the standard deviation of how much bone density differs from the bone mass of an average healthy 30 year old. A score of 0 indicates no deviation from average. The following ranges are used: * T-score of -1.0 or above = normal bone density * T-score between -1.0 and -2.5 = low bone density, or osteopenia * T-score of -2.5 or lower = osteoporosis
Time frame: Baseline to 12 months
Population: Not all patients completed follow-up for this measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Enzalutamide) | Change in Bone Density | -0.23 score on a scale | Standard Deviation 0.26 |
| Arm II (ADT) | Change in Bone Density | 0 score on a scale | Standard Deviation 0.29 |
Secondary
Change in Bone Turnover Markers, as Measured by Bone-specific Alkaline Phosphatase
Will be assessed for each treatment group. Measurements will be taken at day 1 of each course. A paired t-test will test within an arm as to whether the change from baseline to 12 months is significantly different from zero.
Time frame: Baseline and month 12
Population: Patients were compared to themselves as well as across groups. We reviewed difference from month 1 to 12 in order to gather adequate data. Below are the bone-specific alkaline phosphatase. Not all patients completed follow up for this measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Enzalutamide) | Change in Bone Turnover Markers, as Measured by Bone-specific Alkaline Phosphatase | -18.55 microgram/L | Standard Deviation 36.19 |
| Arm II (ADT) | Change in Bone Turnover Markers, as Measured by Bone-specific Alkaline Phosphatase | -58.14 microgram/L | Standard Deviation 133.53 |
Secondary
Change in Bone Turnover Markers as Measured by N-telopeptide
Will be assessed for each treatment group. Measurements will be taken at day 1 of each course. A paired t-test within an arm as to whether the change from baseline to 12 months is significantly different from zero. N-Telopeptide units - nM Bone Collagen Equivalent (BCE).
Time frame: Baseline and 12 months
Population: Patients were compared to themselves as well as across groups. We reviewed difference from month 1 to 12 to gather adequate data. Below are the N-telopeptide. Not all patients completed follow-up for this measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Enzalutamide) | Change in Bone Turnover Markers as Measured by N-telopeptide | -3.05 nM BCE | Standard Deviation 5.51 |
| Arm II (ADT) | Change in Bone Turnover Markers as Measured by N-telopeptide | 1.73 nM BCE | Standard Deviation 8.41 |
Secondary
Change in Fat Mass, as Measured by a DXA Scanner
A paired t-test will test within an arm as to whether the change from baseline to each time point is significantly different from zero.
Time frame: Baseline to up to 12 months
Population: data cannot be reported as the dexa scanner used for the study only measured bone density and not lean body mass (this was realized part way through study).
Secondary
Change in Free Fat Mass, as Measured by a DXA Scanner
A paired t-test will test within an arm as to whether the change from baseline to each time point is significantly different from zero. These data are not able to be reported as the DXA did not measure free fat mass and thus we will be using cross sectional CT analysis.
Time frame: Baseline to up to 12 months
Population: The DXA scanner was not able to analyze free fat mass, only bone density.
Secondary
Change in Markers of Inflammation, as Measured by Circulating Hs-CRP
Mean change in available samples from baseline to 12 months, presented in mg/dL
Time frame: Difference between baseline and 12 months.
Population: Patients were compared to themselves as well as across groups. We reviewed difference from month 1 to 12 in order to gather adequate data. Some patients in the cohort were missing follow-up data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Enzalutamide) | Change in Markers of Inflammation, as Measured by Circulating Hs-CRP | 0.87 mg/dL | Standard Deviation 1.99 |
| Arm II (ADT) | Change in Markers of Inflammation, as Measured by Circulating Hs-CRP | 6.42 mg/dL | Standard Deviation 16.47 |
Secondary
Change in Physical Function, as Measured by Short Physical Performance Battery (SPPB).
The Short SPPB incorporates 3 validated portions to assess a patient's balance and mobility. SPPB scores range from zero to 12 possible points. SPPB score of 3-9 points in persons with no mobility disability indicates frailty; SPPB score of 10 or greater for persons with no sarcopenia and no mobility disability indicates robustness. The higher the score, the better the physical function. Will be measured as a continuous outcome.
Time frame: Difference between baseline and 12 months.
Population: Not all patients completed follow-up for this measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm I (Enzalutamide) | Change in Physical Function, as Measured by Short Physical Performance Battery (SPPB). | 10.58 score on a scale | Standard Deviation 1.39 |
| Arm II (ADT) | Change in Physical Function, as Measured by Short Physical Performance Battery (SPPB). | 10.94 score on a scale | Standard Deviation 1.97 |
Comparison: The results are presented in the following format: N Mean (Std Dev) Median (Q1, Q3). In all cases (Overall, Arm 1, and Arm 2) we fail to reject the null hypothesis that the samples come from the same population of scores at Month 1 versus Month 12 at the 0.05 significance level.p-value: 0.5Wilcoxon (Mann-Whitney)
Secondary
Change in Quality of Life (QOL) Scores, as Measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Sexual Health in Men (SHIM)
The FACT-P is the Functional Assessment of Cancer Therapy - Prostate and measures physical/emotional quality of life in prostate cancer patients. NUMBER OF ITEMS:39 PATIENT POPULATION:Prostate cancer patients 18 years and older RECALL PERIOD:Past 7 days RESPONSE SCALE:5 point Likert-type scale SUBSCALE DOMAINS: Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), Prostate Cancer Subscale (PCS) SCORING: Scores range from 0-158. In general, the higher the score, the better the quality of life. Sexual Health in Men (SHIM). 5 item measure of erectile function. Total score is 1-25 with a higher score indicating better sexual health. Scores: no ED (SHIM total score, 22-25), mild (17-21), mild to moderate (12-16), moderate (8-11), and severe ED (1-7).
Time frame: Baseline to up to 7 months
Population: Patients were compared to themselves as well as across groups. We reviewed difference from month 1 to 7 in order to gather adequate data. Below is the SHIM.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm I (Enzalutamide) | Change in Quality of Life (QOL) Scores, as Measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Sexual Health in Men (SHIM) | SHIM | -3.71 score on a scale | Standard Deviation 5.06 |
| Arm I (Enzalutamide) | Change in Quality of Life (QOL) Scores, as Measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Sexual Health in Men (SHIM) | FACT-P | -4.5 score on a scale | Standard Deviation 10.15 |
| Arm II (ADT) | Change in Quality of Life (QOL) Scores, as Measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Sexual Health in Men (SHIM) | SHIM | -3.4 score on a scale | Standard Deviation 5.98 |
| Arm II (ADT) | Change in Quality of Life (QOL) Scores, as Measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) and Sexual Health in Men (SHIM) | FACT-P | -1.93 score on a scale | Standard Deviation 6.82 |
Secondary
Incidence of Adverse Events, Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.1
The incidence of adverse events has been reported in the adverse events log for clinicaltrials.gov
Time frame: Up to 30 days after the last dose of study drug
Population: adverse events reported in separate section
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I (Enzalutamide) | Incidence of Adverse Events, Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.1 | 10 Participants |
| Arm II (ADT) | Incidence of Adverse Events, Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.1 | 9 Participants |
Secondary
Metabolic Syndrome Incidence, Summarized by the Proportion of Patients With at Least 3 of the 5 Pre-specified Criteria
Metabolic syndrome will be assessed at the beginning of each course and defined by the presence of 3 of the following five traits: abdominal obesity, defined as a waist circumference \> 102 cm (\> 40 in); serum triglycerides \>= 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides; serum HDL cholesterol \< 40 mg/dL (1 mmol/L) or drug treatment for low HDL; blood pressure \>= 130/\>= 85 mmHg or drug treatment for elevated blood pressure; and FPG \>= 100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose.
Time frame: Within the first 6 months of therapy
Population: Includes all patients still participating at this timepoint
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I (Enzalutamide) | Metabolic Syndrome Incidence, Summarized by the Proportion of Patients With at Least 3 of the 5 Pre-specified Criteria | 4 Participants |
| Arm II (ADT) | Metabolic Syndrome Incidence, Summarized by the Proportion of Patients With at Least 3 of the 5 Pre-specified Criteria | 0 Participants |
Secondary
Number of Patients With PSA Progression
PSA progression as defined by an increase in \>= 50% from nadir and an absolute increase of at least 2 ng/mL above the nadir, occurring at least 12 weeks after start of therapy that is confirmed by two consecutive increases taken at least 2 weeks apart. Log rank test will be used to compare the distributions of above variables between the group treated with enzalutamide to the group on standard ADT.
Time frame: Time from randomization to the earliest objective evidence of PSA progression as defined per protocol, assessed up to 30 days after the last dose of study drug
Population: All patients were evaluated throughout the course of the study
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I (Enzalutamide) | Number of Patients With PSA Progression | 0 Participants |
| Arm II (ADT) | Number of Patients With PSA Progression | 1 Participants |
Secondary
Time to Radiographic Progression
Log rank test will be used to compare the distributions of above variables between the group treated with enzalutamide to the group on standard ADT.
Time frame: Time from randomization to the earliest objective evidence of radiographic progression as defined per protocol, assessed up to 30 days after the last dose of study drug
Population: All participants included in analysis.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Arm I (Enzalutamide) | Time to Radiographic Progression | NA Months |
| Arm II (ADT) | Time to Radiographic Progression | 11.474 Months |